• Explore /
  • Poster
  • / Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).

Abstract Poster

Authors

null

Alicia Frances Clare Okines

The Royal Marsden NHS Foundation Trust, London, United Kingdom

Alicia Frances Clare Okines , Jeremy Braybrooke , Iain R. MacPherson , Dr. Stephanie Sutherland , Sacha Jon Howell , Duncan Wheatley , Simon Waters , Rebecca Roylance , Richard D. Baird , Olga Oikonomidou , Carlo Palmieri , Mark Harries , Catherine Harper-Wynne , Amna Sheri , Sarah Khan , Catey Bunce , Kabir Mohammed , Dymphna Lee , Nicholas C. Turner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT04920708

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS1111)

DOI

10.1200/JCO.2023.41.16_suppl.TPS1111

Abstract #

TPS1111

Poster Bd #

332a

Abstract Disclosures

Similar Posters

First Author: Kevin Kalinsky

First Author: Severine Guiu Lahaye

First Author: Cristina I. Truica

First Author: Virginia F. Borges